Skip to main content

Table 4 Survival according to the individual genotypes

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

   n MS (months) p HR (95% CI)
a: All patients      
MTHFR C677T CC 254 54.1 0.412  
  CT 262 82.7   0.88 (0.67-1.15)
  TT 53 n.r.   0.75 (0.46-1.22)
  CC 254 54.1 0.237  
  CT + TT 315 82.7   0.86 (0.66-1.11)
MTHFR A1298C AA 244 82.7 0.036  
  AC 268 47.1   1.31 (1.0-1.72)
  CC 54 74.2   0.77 (0.47-1.28)
  AC 268 47.1 0.016  
  AA + CC 301 82.7   0.73 (0.56-0.94)
   n MS (months) p HR (95% CI)
b: Neoadjuvantly treated patients      
MTHFR C677T CC 161 55.4 0.745  
  CT 179 82.7   0.98 (0.7-1.38)
  TT 29 n.r.   0.77 (0.4-1.51)
  CC 161 55.4 0.77  
  CT + TT 208 82.7   0.95 (0.69-1.32)
MTHFR A1298C AA 156 101.9 0.063  
  AC 179 47.1   1.43 (1.02-2.01)
  CC 31 74.2   0.85 (0.44-1.67)
  AC 179 47.1 0.02  
  AA + CC 190 101.9   0.68 (0.49-0.94)
   n MS (months) p HR (95% CI)
c: Primarily resected patients      
MTHFR C677T CC 93 54.1 0.295  
  CT 83 n.r.   0.72 (0.45-1.15)
  TT 24 66.0   0.69 (0.34-1.4)
  CC 93 54.1 0.119  
  CT + TT 107 66.0   
MTHFR A1298C AA 88 66.0 0.366  
  AC 89 47.6   0.16 (0.74-1.82)
  CC 23 62.2   0.68 (0.31-1.46)
  AC 89 47.6 0.295  
  AA + CC 111 66.0   0.79 (0.52-1.22)